Transcatheter edge-to-edge repair (TEER) was successful in reducing mitral regurgitation (MR) and lowering risk of mortality and heart failure hospitalizations in patients with cardiogenic shock and severe MR, based on an analysis from the STS/ACC TVT Registry presented Sept. 17 during TCT 2022 and simultaneously published in JACC.

Using the STS/ACC TVT Registry, researchers identified 3,797 patients with cardiogenic shock and severe MR who underwent TEER between November 2013 and December 2021. The mean age of patients was 73 years and 59.5% were male. Device success was defined as MR reduction of >1 grade and a final MR grade of <2+. The primary outcome was the impact of device success on one-year mortality or heart failure readmissions.

Overall results showed device success was achieved in 85.6% of patients. At one-year post-TEER, researchers noted that device success was associated with significantly lower all-cause mortality (34.6% vs. 55.5%; p<0.001), along with a lower composite of mortality or heart failure admissions (29.6% vs. 45.2%; p<0.001).

"The current data supports the rationale of randomized studies to prospectively establish efficacy of this therapy in this patient cohort," concludes Trevor Simard, MD, et al.

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Cardiac Surgery and VHD, Interventions and Structural Heart Disease, Mitral Regurgitation

Keywords: Mitral Valve Insufficiency, Mitral Valve, Heart Valve Prosthesis Implantation, TCT22, Transcatheter Cardiovascular Therapeutics, National Cardiovascular Data Registries, STS/ACC TVT Registry

< Back to Listings